1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT

Biotech Will Need Cash To Finalize Pivotal Program

 
• By Mandy Jackson

Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.

Schizophrenia and split personality disorder and mental health psychiatric disease concept
Reviva plans to also develop its drug for bipolar disorder, depression and ADHD • Source: Shutterstock

Reviva Pharmaceuticals Holdings, Inc. saw its stock price jump nearly 50% on 30 October after the small-cap company reported that brilaroxazine succeeded in its first Phase III clinical trial in schizophrenia with results that look just as good and potentially slightly better than data for KarXT, which caused Karuna Therapeutics, Inc.’s valuation to double last year.

Key Takeaways

  • Reviva reported positive results from the first Phase III trial of its selective serotonin and dopamine modulator brilaroxazine in schizophrenia.

KarXT has become one of the most closely watched new drugs in neuropsychiatry after the company delivered results from the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.